{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:28:03Z","timestamp":1787696883086,"version":"build-2784847793"},"reference-count":57,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Interdisciplinary Thematic Institute IMCBio"},{"DOI":"10.13039\/501100003768","name":"University of Strasbourg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003768","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007175","name":"CNRS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007175","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Inserm","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"name":"IdEx Unistra","award":["ANR-10-IDEX-0002"],"award-info":[{"award-number":["ANR-10-IDEX-0002"]}]},{"name":"SFRI-STRAT\u2019US project","award":["ANR 20-SFRI-0012"],"award-info":[{"award-number":["ANR 20-SFRI-0012"]}]},{"name":"EUR IMCBio","award":["ANR- 17-EURE-0023"],"award-info":[{"award-number":["ANR- 17-EURE-0023"]}]},{"name":"French Investments for the Future Program"},{"name":"ANR DynANR","award":["ANR-23-CE17-0002"],"award-info":[{"award-number":["ANR-23-CE17-0002"]}]},{"name":"Roland Sackers"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Centronuclear myopathies (CNM) are rare congenital disorders characterized by muscle weakness and disorganization of myofibres. These conditions can result from dominant mutations in the DNM2 gene encoding the GTPase dynamin, making them potential targets for antisense therapy. Preclinical studies suggested decreasing DNM2 as a therapy but a recent clinical trial with antisense oligonucleotides did not effectively address the disease and showed some non-muscle toxicity.<\/jats:p>\n                  <jats:p>Here, to promote DNM2 downregulation in muscle versus other tissues, we used an exon skipping peptide-conjugated phosphorodiamidate morpholino (PPMO) targeting Dnm2 exon 6 splicing in the Dnm2R369W\/+ mouse model for the moderate CNM form.<\/jats:p>\n                  <jats:p>Intravenous administration of PPMOs at an early age (4 weeks) significantly downregulated intact (i.e. normally spliced) Dnm2 mRNA (\u223c50%) and DNM2 protein levels in muscle. This intervention led to a rescue of muscle force, thereby preventing disease progression. PPMO administration at a later age (8 weeks), when mice demonstrated established phenotypes, efficiently decreased intact Dnm2 mRNA and protein levels in muscle, resulting in reversal of the disease phenotype and significant improvement in muscle force (from 11\u2005mN\/mg to nearly 16\u2005mN\/mg).<\/jats:p>\n                  <jats:p>Overall, our results indicate that PPMOs targeting Dnm2 splicing effectively decrease intact Dnm2 mRNA and protein levels in muscle and rescue muscle force in Dnm2R369W\/+ mice, suggesting a promising translational approach for patients with DNM2 mutations and potentially other forms of CNM. More generally, it provides the concept of using the exon skipping strategy to decrease the protein expression of a target gene, rather than producing a shorter functional protein as is generally done.<\/jats:p>","DOI":"10.1093\/brain\/awaf249","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T07:51:57Z","timestamp":1751529117000},"page":"4495-4507","source":"Crossref","is-referenced-by-count":5,"title":["Exon skipping peptide-conjugated morpholinos downregulate dynamin 2 to rescue centronuclear myopathy"],"prefix":"10.1093","volume":"148","author":[{"given":"Foteini","family":"Moschovaki-Filippidou","sequence":"first","affiliation":[{"name":"IGBMC (Institut de G\u00e9n\u00e9tique et de Biologie Mol\u00e9culaire et Cellulaire), Inserm U1258, CNRS UMR7104, Universit\u00e9 de Strasbourg , Illkirch 67404 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"de Carvalho Neves","sequence":"additional","affiliation":[{"name":"IGBMC (Institut de G\u00e9n\u00e9tique et de Biologie Mol\u00e9culaire et Cellulaire), Inserm U1258, CNRS UMR7104, Universit\u00e9 de Strasbourg , Illkirch 67404 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nad\u00e8ge","family":"Diedhiou","sequence":"additional","affiliation":[{"name":"IGBMC (Institut de G\u00e9n\u00e9tique et de Biologie Mol\u00e9culaire et Cellulaire), Inserm U1258, CNRS UMR7104, Universit\u00e9 de Strasbourg , Illkirch 67404 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahya","family":"Jad","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Institute of Developmental and Regenerative Medicine (IDRM), University of Oxford , Oxford OX3 7FZ ,","place":["UK"]},{"name":"MDUK Oxford Neuromuscular Centre , Department of Paediatrics, Oxford OX3 9DU ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8019-9504","authenticated-orcid":false,"given":"Johann","family":"B\u00f6hm","sequence":"additional","affiliation":[{"name":"IGBMC (Institut de G\u00e9n\u00e9tique et de Biologie Mol\u00e9culaire et Cellulaire), Inserm U1258, CNRS UMR7104, Universit\u00e9 de Strasbourg , Illkirch 67404 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J A","family":"Wood","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Institute of Developmental and Regenerative Medicine (IDRM), University of Oxford , Oxford OX3 7FZ ,","place":["UK"]},{"name":"MDUK Oxford Neuromuscular Centre , Department of Paediatrics, Oxford OX3 9DU ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A","family":"Varela","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Institute of Developmental and Regenerative Medicine (IDRM), University of Oxford , Oxford OX3 7FZ ,","place":["UK"]},{"name":"MDUK Oxford Neuromuscular Centre , Department of Paediatrics, Oxford OX3 9DU ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8256-5862","authenticated-orcid":false,"given":"Jocelyn","family":"Laporte","sequence":"additional","affiliation":[{"name":"IGBMC (Institut de G\u00e9n\u00e9tique et de Biologie Mol\u00e9culaire et Cellulaire), Inserm U1258, CNRS UMR7104, Universit\u00e9 de Strasbourg , Illkirch 67404 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"key":"2025120423112696500_awaf249-B1","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1750-1172-3-26","article-title":"Centronuclear (myotubular) myopathy","volume":"3","author":"Jungbluth","year":"2008","journal-title":"Orphanet J Rare Dis"},{"key":"2025120423112696500_awaf249-B2","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.nmd.2010.01.014","article-title":"Centronuclear myopathies: A widening concept","volume":"20","author":"Romero","year":"2010","journal-title":"Neuromuscul Disord"},{"key":"2025120423112696500_awaf249-B3","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/dmcn.14365","article-title":"Congenital myopathies: An update","volume":"62","author":"Claeys","year":"2020","journal-title":"Dev Med Child Neurol"},{"key":"2025120423112696500_awaf249-B4","doi-asserted-by":"crossref","first-page":"761636","DOI":"10.3389\/fneur.2021.761636","article-title":"A systematic review and meta-analysis of the prevalence of congenital myopathy","volume":"12","author":"Huang","year":"2021","journal-title":"Front Neurol"},{"key":"2025120423112696500_awaf249-B5","doi-asserted-by":"crossref","first-page":"857959","DOI":"10.3389\/fneur.2022.857959","article-title":"Corrigendum: A systematic review and meta-analysis of the prevalence of congenital myopathy","volume":"13","author":"Huang","year":"2022","journal-title":"Front Neurol"},{"key":"2025120423112696500_awaf249-B6","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/archdischild-2019-317910","article-title":"Mortality and respiratory support in X-linked myotubular myopathy: A RECENSUS retrospective analysis","volume":"105","author":"Graham","year":"2020","journal-title":"Arch Dis Child"},{"key":"2025120423112696500_awaf249-B7","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0960-8966(02)00153-0","article-title":"Genotype-phenotype correlations in X-linked myotubular myopathy","volume":"12","author":"McEntagart","year":"2002","journal-title":"Neuromuscul Disord"},{"key":"2025120423112696500_awaf249-B8","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.semcdb.2016.08.004","article-title":"Current and future therapeutic approaches to the congenital myopathies","volume":"64","author":"Jungbluth","year":"2017","journal-title":"Semin Cell Dev Biol"},{"key":"2025120423112696500_awaf249-B9","doi-asserted-by":"crossref","first-page":"11377","DOI":"10.3390\/ijms222111377","article-title":"Common pathogenic mechanisms in centronuclear and myotubular myopathies and latest treatment advances","volume":"22","author":"G\u00f3mez-Oca","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2025120423112696500_awaf249-B10","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/ng0696-175","article-title":"A gene mutated in X-linked myotubular myopathy defines a new putative tyrosine phosphatase family conserved in yeast","volume":"13","author":"Laporte","year":"1996","journal-title":"Nat Genet"},{"key":"2025120423112696500_awaf249-B11","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/ng1657","article-title":"Mutations in dynamin 2 cause dominant centronuclear myopathy","volume":"37","author":"Bitoun","year":"2005","journal-title":"Nat Genet"},{"key":"2025120423112696500_awaf249-B12","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/ng2086","article-title":"Mutations in amphiphysin 2 (BIN1) disrupt interaction with dynamin 2 and cause autosomal recessive centronuclear myopathy","volume":"39","author":"Nicot","year":"2007","journal-title":"Nat Genet"},{"key":"2025120423112696500_awaf249-B13","doi-asserted-by":"crossref","first-page":"6274","DOI":"10.3390\/ijms23116274","article-title":"Centronuclear myopathy caused by defective membrane remodelling of dynamin 2 and BIN1 variants","volume":"23","author":"Fujise","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2025120423112696500_awaf249-B14","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/humu.22067","article-title":"Mutation spectrum in the large GTPase dynamin 2, and genotype-phenotype correlation in autosomal dominant centronuclear myopathy","volume":"33","author":"B\u00f6hm","year":"2012","journal-title":"Hum Mutat"},{"key":"2025120423112696500_awaf249-B15","doi-asserted-by":"crossref","first-page":"102174","DOI":"10.1016\/j.ceb.2023.102174","article-title":"Dynamins in human diseases: Differential requirement of dynamin activity in distinct tissues","volume":"81","author":"Laiman","year":"2023","journal-title":"Curr Opin Cell Biol"},{"key":"2025120423112696500_awaf249-B16","doi-asserted-by":"crossref","first-page":"5542","DOI":"10.1093\/hmg\/ddv285","article-title":"Dynamin-2 mutations associated with centronuclear myopathy are hypermorphic and lead to T-tubule fragmentation","volume":"24","author":"Chin","year":"2015","journal-title":"Hum Mol Genet"},{"key":"2025120423112696500_awaf249-B17","doi-asserted-by":"crossref","first-page":"22753","DOI":"10.1074\/jbc.C110.130013","article-title":"Dynamin 2 mutants linked to centronuclear myopathies form abnormally stable polymers","volume":"285","author":"Wang","year":"2010","journal-title":"J Biol Chem"},{"key":"2025120423112696500_awaf249-B18","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1016\/j.ajpath.2011.01.054","article-title":"Increased expression of wild-type or a centronuclear myopathy mutant of dynamin 2 in skeletal muscle of adult mice leads to structural defects and muscle weakness","volume":"178","author":"Cowling","year":"2011","journal-title":"Am J Pathol"},{"key":"2025120423112696500_awaf249-B19","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1172\/JCI46267","article-title":"Mice lacking microRNA 133a develop dynamin 2-dependent centronuclear myopathy","volume":"121","author":"Liu","year":"2011","journal-title":"J Clin Invest"},{"key":"2025120423112696500_awaf249-B20","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1172\/JCI71206","article-title":"Reducing dynamin 2 expression rescues X-linked centronuclear myopathy","volume":"124","author":"Cowling","year":"2014","journal-title":"J Clin Invest"},{"key":"2025120423112696500_awaf249-B21","doi-asserted-by":"crossref","first-page":"11066","DOI":"10.1073\/pnas.1808170115","article-title":"Reducing dynamin 2 (DNM2) rescues DNM2-related dominant centronuclear myopathy","volume":"115","author":"Buono","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"2025120423112696500_awaf249-B22","doi-asserted-by":"crossref","first-page":"15661","DOI":"10.1038\/ncomms15661","article-title":"Antisense oligonucleotide-mediated Dnm2 knockdown prevents and reverts myotubular myopathy in mice","volume":"8","author":"Tasfaout","year":"2017","journal-title":"Nat Commun"},{"key":"2025120423112696500_awaf249-B23","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.ymthe.2021.08.006","article-title":"Mice with muscle-specific deletion of Bin1 recapitulate centronuclear myopathy and acute downregulation of dynamin 2 improves their phenotypes","volume":"30","author":"Silva-Rojas","year":"2022","journal-title":"Mol Ther"},{"key":"2025120423112696500_awaf249-B24","author":"Dynacure"},{"key":"2025120423112696500_awaf249-B25","author":"Freitag"},{"key":"2025120423112696500_awaf249-B26","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s12038-023-00365-z","article-title":"Morpholino oligonucleotide-mediated exon skipping for DMD treatment: Past insights, present challenges and future perspectives","volume":"48","author":"Gupta","year":"2023","journal-title":"J Biosci"},{"key":"2025120423112696500_awaf249-B27","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.ebiom.2019.06.036","article-title":"Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases","volume":"45","author":"Tsoumpra","year":"2019","journal-title":"EBioMedicine"},{"key":"2025120423112696500_awaf249-B28","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.3390\/molecules14031304","article-title":"Gene knockdowns in adult animals: PPMOs and vivo-morpholinos","volume":"14","author":"Moulton","year":"2009","journal-title":"Molecules"},{"key":"2025120423112696500_awaf249-B29","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1021\/bc070060v","article-title":"Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate","volume":"18","author":"Amantana","year":"2007","journal-title":"Bioconjug Chem"},{"key":"2025120423112696500_awaf249-B30","doi-asserted-by":"crossref","first-page":"6418","DOI":"10.1093\/nar\/gkn671","article-title":"Improved cell-penetrating peptide-PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle","volume":"36","author":"Ivanova","year":"2008","journal-title":"Nucleic Acids Res"},{"key":"2025120423112696500_awaf249-B31","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1172\/JCI128205","article-title":"Peptide-conjugated oligonucleotides evoke long-lasting myotonic dystrophy correction in patient-derived cells and mice","volume":"129","author":"Klein","year":"2019","journal-title":"J Clin Invest"},{"key":"2025120423112696500_awaf249-B32","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.omtn.2022.02.003","article-title":"Proof of concept of peptide-linked blockmiR-induced MBNL functional rescue in myotonic dystrophy type 1 mouse model","volume":"27","author":"Overby","year":"2022","journal-title":"Mol Ther Nucleic Acids"},{"key":"2025120423112696500_awaf249-B33","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1089\/nat.2020.0907","article-title":"Immortalized canine dystrophic myoblast cell lines for development of peptide-conjugated splice-switching oligonucleotides","volume":"31","author":"Tone","year":"2021","journal-title":"Nucleic Acid Ther"},{"key":"2025120423112696500_awaf249-B34","doi-asserted-by":"crossref","first-page":"102024","DOI":"10.1016\/j.omtn.2023.09.001","article-title":"Peptide-conjugated antimiRs improve myotonic dystrophy type 1 phenotypes by promoting endogenous MBNL1 expression","volume":"34","author":"Gonz\u00e1lez-Mart\u00ednez","year":"2023","journal-title":"Mol Ther Nucleic Acids"},{"key":"2025120423112696500_awaf249-B35","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1093\/hmg\/ddg196","article-title":"Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle","volume":"12","author":"Gebski","year":"2003","journal-title":"Hum Mol Genet"},{"key":"2025120423112696500_awaf249-B36","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.omtn.2022.08.019","article-title":"A cell-penetrating peptide enhances delivery and efficacy of phosphorodiamidate morpholino oligomers in mdx mice","volume":"30","author":"Gan","year":"2022","journal-title":"Mol Ther Nucleic Acids"},{"key":"2025120423112696500_awaf249-B37","doi-asserted-by":"crossref","first-page":"175675","DOI":"10.1016\/j.ejphar.2023.175675","article-title":"Duchenne muscular dystrophy: Current treatment and emerging exon skipping and gene therapy approach","volume":"947","author":"Patterson","year":"2023","journal-title":"Eur J Pharmacol"},{"key":"2025120423112696500_awaf249-B38","doi-asserted-by":"crossref","first-page":"6849","DOI":"10.1038\/s41467-022-34490-4","article-title":"Differential impact of ubiquitous and muscle dynamin 2 isoforms in muscle physiology and centronuclear myopathy","volume":"13","author":"G\u00f3mez-Oca","year":"2022","journal-title":"Nat Commun"},{"key":"2025120423112696500_awaf249-B39","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1091\/mbc.e08-08-0890","article-title":"Isoform and splice-variant specific functions of dynamin-2 revealed by analysis of conditional knock-out cells","volume":"19","author":"Liu","year":"2008","journal-title":"Mol Biol Cell"},{"key":"2025120423112696500_awaf249-B40","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1172\/JCI90542","article-title":"Amphiphysin (BIN1) negatively regulates dynamin 2 for normal muscle maturation","volume":"127","author":"Cowling","year":"2017","journal-title":"J Clin Invest"},{"key":"2025120423112696500_awaf249-B41","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.omtn.2023.07.003","article-title":"DNM2 levels normalization improves muscle phenotypes of a novel mouse model for moderate centronuclear myopathy","volume":"33","author":"de Carvalho Neves","year":"2023","journal-title":"Mol Ther Nucleic Acids"},{"key":"2025120423112696500_awaf249-B42","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/978-1-4939-6817-6_2","article-title":"Making a morpholino experiment work: Controls, favoring specificity, improving efficacy, storage, and dose","volume":"1565","author":"Moulton","year":"2017","journal-title":"Methods Mol Biol"},{"key":"2025120423112696500_awaf249-B43","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1038\/mtna.2012.30","article-title":"Pip6-PMO, a new generation of peptide-oligonucleotide conjugates with improved cardiac exon skipping activity for DMD treatment","volume":"1","author":"Betts","year":"2012","journal-title":"Mol Ther Nucleic Acids"},{"key":"2025120423112696500_awaf249-B44","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/978-1-0716-2772-3_13","article-title":"Peptide-conjugated PMOs for the treatment of myotonic dystrophy","volume":"2587","author":"Stoodley","year":"2023","journal-title":"Methods Mol Biol"},{"key":"2025120423112696500_awaf249-B45","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3758\/BF03193146","article-title":"G*power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences","volume":"39","author":"Faul","year":"2007","journal-title":"Behav Res Methods"},{"key":"2025120423112696500_awaf249-B46","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ab.2010.02.036","article-title":"Reversible Ponceau staining as a loading control alternative to actin in Western blots","volume":"401","author":"Romero-Calvo","year":"2010","journal-title":"Anal Biochem"},{"key":"2025120423112696500_awaf249-B47","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41592-020-01018-x","article-title":"Cellpose: A generalist algorithm for cellular segmentation","volume":"18","author":"Stringer","year":"2021","journal-title":"Nat Methods"},{"key":"2025120423112696500_awaf249-B48","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: An open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat Methods"},{"key":"2025120423112696500_awaf249-B49","doi-asserted-by":"crossref","first-page":"18240","DOI":"10.1038\/srep18240","article-title":"MicroRNA 19a replacement partially rescues fin and cardiac defects in zebrafish model of Holt Oram syndrome","volume":"5","author":"Chiavacci","year":"2015","journal-title":"Sci Rep"},{"key":"2025120423112696500_awaf249-B50","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1038\/emboj.2010.187","article-title":"Dynamin GTPase regulation is altered by PH domain mutations found in centronuclear myopathy patients","volume":"29","author":"Kenniston","year":"2010","journal-title":"EMBO J"},{"key":"2025120423112696500_awaf249-B51","doi-asserted-by":"crossref","first-page":"100077","DOI":"10.1074\/jbc.RA120.015184","article-title":"Mutant BIN1-Dynamin 2 complexes dysregulate membrane remodeling in the pathogenesis of centronuclear myopathy","volume":"296","author":"Fujise","year":"2021","journal-title":"J Biol Chem"},{"key":"2025120423112696500_awaf249-B52","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.ymthe.2018.02.008","article-title":"Single intramuscular injection of AAV-shRNA reduces DNM2 and prevents myotubular myopathy in mice","volume":"26","author":"Tasfaout","year":"2018","journal-title":"Mol Ther"},{"key":"2025120423112696500_awaf249-B53","doi-asserted-by":"crossref","first-page":"10962","DOI":"10.1073\/pnas.1605731113","article-title":"Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy","volume":"113","author":"Hammond","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"2025120423112696500_awaf249-B54","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.3390\/ijms24032697","article-title":"Application of antisense conjugates for the treatment of myotonic dystrophy type 1","volume":"24","author":"Stoodley","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2025120423112696500_awaf249-B55","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1089\/hum.2013.052","article-title":"Exon skipping as a therapeutic strategy applied to an RYR1 mutation with pseudo-exon inclusion causing a severe core myopathy","volume":"24","author":"Rendu","year":"2013","journal-title":"Hum Gene Ther"},{"key":"2025120423112696500_awaf249-B56","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/14712598.2023.2169070","article-title":"Next steps for the optimization of exon therapy for Duchenne muscular dystrophy","volume":"23","author":"Filonova","year":"2023","journal-title":"Expert Opin Biol Ther"},{"key":"2025120423112696500_awaf249-B57","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1089\/hum.2023.29242.ddu","article-title":"Duchenne muscular dystrophy gene therapy in 2023: Status, perspective, and beyond","volume":"34","author":"Duan","year":"2023","journal-title":"Hum Gene Ther"}],"container-title":["Brain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/brain\/advance-article-pdf\/doi\/10.1093\/brain\/awaf249\/63662081\/awaf249.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/148\/12\/4495\/63662081\/awaf249.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/148\/12\/4495\/63662081\/awaf249.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T04:11:41Z","timestamp":1764907901000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/brain\/article\/148\/12\/4495\/8185529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":57,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,7,3]]},"published-print":{"date-parts":[[2025,12,4]]}},"URL":"https:\/\/doi.org\/10.1093\/brain\/awaf249","relation":{},"ISSN":["0006-8950","1460-2156"],"issn-type":[{"value":"0006-8950","type":"print"},{"value":"1460-2156","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,7,3]]}}}